L'Oréal has increased its ownership stake in Galderma to 20%, reinforcing the French beauty giant's position in the medical-aesthetics supply chain. The move reflects L'Oréal's long-term confidence in Galderma's Restylane (HA filler) and Sculptra (PLLA biostimulator) portfolios, both of which command significant market share among independent practices and dermatology groups.